One caveat is that cortical thickness is only one possible measure of brain health and ideally a more holistic assessment which integrates several modalities, like gray matter volume and thickness, white-matter integrity, and absence of amyloid and tau protein accumulation, should be used. The gene discussed is MAPT; the disease is amyloidosis.